psalexa
logo

mTOR Inhibitors Therapeutics - Pipeline Analysis 2017

mTOR Inhibitors Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Published: December 2017
Report Code: LS11360
Available Format:
Pages: 124

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Overview

mTOR (mechanistic/mammalian target of rapamycin) plays an important role in the development and proliferation of the body cells and acts on protein kinase complexes, such as mTOR complex 1 and 2 (mTORC1/2). Rapamycin, the first inhibitor of mTOR, has been approved as an immunosuppressant, that blocks T-cell activation and has been in use since 2000 for the prevention of kidney graft rejection. Temsirolimus, a drug manufactured by Pfizer Inc., used for the treatment of advanced renal cell carcinoma has been approved by the USFDA in 2007.

 

mTOR INHIBITORS THERAPEUTICS UNDER DEVELOPMENT (2017)

mTOR INHIBITORS THERAPEUTICS

 

Further Pfizer Inc. is in the process of developing gedatolisib (PF-05212384) that deregulates the phosphoinositide 3-kinase (PI3K) and mTOR signaling pathways, for the treatment of acute myeloid leukemia, colorectal cancer, non-small cell lung cancer and breast cancer. Most of the drug candidates in the pipeline are being developed to be administered by the oral route of administration.

Pipeline Analysis

As of December 2017, the mTOR inhibitors therapeutics pipeline comprises of 30 drug candidates in different stages of development.

Competitive Landscape

Some of the key players involved in the development of mTOR inhibitors therapeutics include F. Hoffman-La-Roche AG, Pfizer Inc., and resTORbio Inc.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry